GlobalData on MSN1d
Teva’s long-lasting schizophrenia injectable shines in Phase III
Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...
Bristol-Myers Squibb Company (NYSE:BMY) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...
News Tribune4d
Promising schizophrenia drug shows mixed results
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.
BMY Beats Analyst Estimates
Bristol Myers Squibb reported strong third-quarter financial results, notching an 18% jump in its growth portfolio.